CPDA

• Description:

  CPDA is a novel potent SH2 domain-containing inositol phosphatase 2 (SHIP2) inhibitor.

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  Phosphatase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/CPDA.html

• Purity:

  99.36

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  O=C(NC1=NC=CC(OCC2=CC=C(Cl)C=C2)=C1)CC3=C(F)C=CC=C3F

• Molecular Formula:

  C20H15ClF2N2O2

• Molecular Weight:

  388.80

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5'-phosphatase 2 (SHIP2) . Eur J Med Chem. 2013 Apr;62:649-660.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1415834-63-7